Skip to main content
All lobbying filings

PHLOW CORPORATION

Lobbying for PHLOW CORPORATION

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$400,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Virginia

Official filing document

 Government bodies contacted 6
  • Defense, Dept of (DOD)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • Natl Economic Council (NEC)
  • Office of Management & Budget (OMB)
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
 Lobbying activity 3
Budget/Appropriations

FY27 Labor, Health and Human Services, Education, and Related Agencies Appropriations (no bill numbers); FY27 Department of Defense Appropriations (no bill numbers)

Health Issues

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Manufacturing

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem